| ¿µ¹® | Coombs test | ÇÑ±Û | Å©¿òÁî°Ë»ç |
|---|---|---|---|
| ¼³¸í | ÀûÇ÷±¸¿¡ ´ëÇÑ Ç×ü¸¦ °Ë»çÇÏ´Â ¹æ¹ý. Ç×ü¶õ ƯÁ¤ÇÑ ¹°Áú¿¡ ºÎÂøµÇ¾î ±× ¹°ÁúÀÇ ÀÛ¿ëÀ» ¾ïÁ¦Çϰí, ¶Ç´Â ±× ¹°ÁúÀ» ÆÄ±«ÇÏ´Â °ÍÀ¸·Î B-¸²ÇÁ±¸¶ó´Â ¸é¿ªÀ» ´ã´çÇÏ´Â ¼¼Æ÷¿¡ ÀÇÇØ¼ ¸¸µé¾îÁø´Ù. ÀÌ Å©¿òÁî°Ë»ç¿¡´Â Á÷Á¢Å©¿òÁî°Ë»ç¿Í °£Á¢Å©¿òÁî°Ë»çÀÇ µÎ °¡Áö°¡ Àִµ¥ Á÷Á¢ Å©¿òÁî°Ë»ç´Â ¸ö¼ÓÀÇ ÀûÇ÷±¸¿¡ Á÷Á¢ ºÎÂøµÇ¾î ÀÖ´Â Ç×ü¸¦ °Ë»çÇÏ´Â ¹æ¹ýÀÌ´Ù. äÃëÇÑ Ç÷¾×À» ÀûÇ÷±¸¸¦ ¾ò¾î¼ »ç¶÷ÀÇ Ç×ü¿¡ ´ëÇÑ Ç×ü(»ç¶÷ÀÇ Ç×ü¿¡ ƯÁ¤ÇÏ°Ô ºÎÂøÀÌ µÇ´Â Ç×ü)¸¦ ¹ÝÀÀ½Ã۸é, ¸¸¾à ÀûÇ÷±¸¿¡ ´ëÇÑ Ç×ü°¡ ºÎÂøµÇ¾î ÀÖ´Â ÀûÇ÷±¸¶ó¸é »ç¶÷ÀÇ Ç×ü¿¡ ´ëÇÑ Ç×ü°¡, ÀÛ¿ëÇÏ¿© ħ° ¹ÝÀÀÀÌ ÀϾ°Ô µÇ°í Ç×ü°¡ ºÎÂøµÇ¾î ÀÖÁö ¾Ê´Â ÀûÇ÷±¸ÀÌ¸é ¹ÝÀÀÀÌ ÀϾÁö ¾Ê´Â °ÍÀ» ÀÌ¿ëÇÑ´Ù. °£Á¢Å©¿òÁî°Ë»ç´Â Ç÷Àå¼Ó¿¡ Á¸ÀçÇÏ´Â ÀûÇ÷±¸¿Í ºÎÂøµÇ¾î ÀÖÁö ¾ÊÀº Ç×ü¸¦ ã¾Æ³»´Â ½ÃÇèÀ¸·Î Ç÷ÀåÀ» äÃëÇØ¼ ´Ù¸¥ »ç¶÷ÀÇ ÀûÇ÷±¸¿Í ¹ÝÀÀÀ» ½ÃŰ°í ¿ª½Ã Ç×ü¿¡ ´ëÇÑ Ç×ü¸¦ ¹ÝÀÀ½ÃÄÑ Ä§°¹ÝÀÀÀ» °üÂûÇØ¼ ±× Ç×ü¸¦ ã¾Æ³»´Â ¹æ¹ýÀÌ´Ù. |
||
| ¿µ¹® | tuberculin test | ÇÑ±Û | Æ©º£¸£Ä𸰰˻ç |
|---|---|---|---|
| ¼³¸í | ¸¹Àº ¼·Î ´Ù¸¥ ÇüÅÂÀÇ Æ©º£¸£Ä𸰰ú ´Ù¾çÇÑ Åõ¿©¹æ¹ý¿¡ ÀÇÇÑ ¸ðµç Á¾·ùÀÇ °áÇÙ ÇǺΰ˻ç¹ý. ÇöÀç Ç¥ÁØ ½ÃÇè¹ýÀ¸·Î µÇ¾îÀÖ´Â °¡Àå ½Åºù¼ºÀÖ´Â °Ë»ç·Î´Â PPD¸¦ Çdz»ÁÖ»çÇÏ´Â ¹æ¹ý¸ÁÅä¿ì °Ë»çÀÌ´Ù. Çdz»ÁÖ»çÈÄ 48~72½Ã°£ ÈÄ¿¡ ÁÖ»çºÎÀ§¿¡ Á÷°æ 10mmÀÌ»óÀ¸·Î º¸À̸ç, ¸¸Á®Áö´Â È«¹Ý°ú °æÈ°¡ ³ªÅ¸³ª¸é ¾ç¼ºÀÌ´Ù. ¼ºÀο¡°Ô´Â ÀϹÝÀûÀ¸·Î Áß°£ °µµÀÇ Æ©º£¸£Äð¸°(5Tu)À» »ç¿ëÇϸç, ¾ç¼º¹ÝÀÀÀÌ ³ªÅ¸³ª¸é °áÇÙ±Õ¿¡ ÀÌÀü¿¡ °¨¿°µÇ¾ú°Å³ª ÇöÀç °¨¿°µÇ¾î ÀÖ´Ù´Â È®Á¤Àû Áø´ÜÀÌ µÈ´Ù. À½¼º¹ÝÀÀÀº °áÇÙÀÌ ¾ø°Å³ª, ½ÉÇÑ °áÇÙ°¨¿°¿¡ ÀÇÇÑ ÇǺξ˷¹¸£±â°¡ ÀÖÀ» °æ¿ì, ¶Ç´Â ¸é¿ª¾ïÁ¦¸¦ ³ªÅ¸³»´Â º´, ¿¹¸¦ µé¸é È£ÁöŲº´À̳ª »ç¸£ÄÚÀ̵åÁõ µîÀÌ ÇÕº´µÈ °æ¿ìÀÌ´Ù. |
||
| ¿µ¹® | Papanicolaou smear(test) | ÇÑ±Û | ÆÄÆÄ´ÏÄÝ·Î µµ¸»°Ë»ç |
|---|---|---|---|
| ¼³¸í | ÁÙ¿©¼ ÆËµµ¸»°Ë»ç(Pap smear)À̶ó°í ºÎ¸¥´Ù. ¿©¼ºÀÇ Àڱøñ¾ÏÀÇ ¹ß»ýÀ» ¹Ì¸® ¾Ë¾Æº¸±â À§ÇØ ½ÃÇàÇÏ´Â °Ë»ç¹ýÀ¸·Î ¹Ì±¹¿¡¼´Â ÀÌ ¹æ¹ýÀ¸·Î ÇöÀç Àڱøñ¾Ï¹ß»ý¿¡ ÀÇÇÑ »ç¸Á·üÀ» ÇöÀúÈ÷ ³·Ãß°í ÀÖ´Ù. ¹æ¹ýÀº »êºÎÀΰú¿¡¼ ½ÃÇàÇϸç, ¿©¼ºÀÇ Àڱøñ¿¡¼ ¼¼Æ÷¸¦ °¡Á®´Ù°¡ µµ¸»ÇÏ¿© Çö¹Ì°æÀ¸·Î °Ë»çÇÑ´Ù. ¿äÁîÀ½¿¡ ¿Í¼´Â Àڱøñ»Ó ¾Æ´Ï¶ó È£Èí±â³ª ºñ´¢±â µî ºÐºñ¹°À» µµ¸»ÇÏ¿© ÆÄÆÄ´ÏÄÝ·Î ¿°»öÀ» ÇÏ¿© °Ë»çÇÏ´Â °Íµµ ¿©±â¿¡ Æ÷ÇԵȴÙ. (±×¸² P-3). |
||
| ¿µ¹® | glucose tolerance test | ÇÑ±Û | Æ÷µµ´ç°ßµõ°Ë»ç |
|---|---|---|---|
| ¼³¸í | Æ÷µµ´ç°ßµõ °Ë»ç¶õ ´ç´¢º´ÀÇ Áø´Ü¿¡ »ç¿ëµÇ´Â °Ë»ç·Î ´çÀ» ü³»¿¡ Åõ¿©ÇÏ°í ½Ã°£ º°·Î Ç÷¾×À» äÃëÇÏ¿© Ç÷´çÀÇ ³óµµ¸¦ Àç¾î¼ °íÇ÷´ç ¿©ºÎ¸¦ Á¶»çÇÏ´Â °Ë»çÀÌ´Ù. ÁÖ·Î °æ±¸Æ÷µµ´ç°ßµõ°Ë»ç(oral glucose tolerance test)¸¦ ¸¹ÀÌ Çϴµ¥ À̰ÍÀº 10~16½Ã°£ÀÇ ±Ý½Ä ÈÄ¿¡ äÇ÷À» Çѹø Çѵڿ¡ µµ´ç 75gÀ» 250~300mLÀÇ ¹°¿¡ ³ì¿© 5ºÐ¿¡ °ÉÃļ ¸¶½Ã°Ô ÇÏ°í ¸Å½Ã°£ º°·Î äÇ÷À» ÇÏ¿© Ç÷´çÀÇ ³óµµ¸¦ ýũÇÑ´Ù. °øº¹½Ã¿¡ Á¤¸Æ¿¡¼ äÇ÷ÇÏ¿© ÃøÁ¤ÇÑ Ç÷´çÀÌ 140mg/dLÀÌ»óÀ̰ųª Æ÷µµ´ç°ßµõ °Ë»ç 2½Ã°£ÈÄÀÇ Ç÷´çÀÌ 200mg/dLÀÌ»óÀÏ °æ¿ì¿¡´Â ´ç´¢º´À¸·Î Áø´ÜÀ» ÇÑ´Ù. ±×·¯³ª ÀÌ °Ë»ç¸¦ ½Ç½ÃÇÒ °æ¿ì¿¡ ÁÖÀÇÇØ¾ß ÇÒ Á¡Àº °Ë»çÀü 3Àϰ£ ÇÏ·ç¿¡ 150gÀÌ»óÀÇ Åº¼öȹ°À» ¼·ÃëÇØ¾ß ÇÑ´Ù´Â °Í°ú °Ë»çµµÁß¿¡ ¿îµ¿, Èí¿¬ µîÀ» ÇÏÁö ¾Ê¾Æ¾ß ÇÑ´Ù´Â °ÍÀÌ´Ù. |
||
| ¿µ¹® | blood test | ÇÑ±Û | Ç÷¾×°Ë»ç |
|---|---|---|---|
| ¼³¸í | Ç÷¾×ÇüÀ̳ª Áúº´ À¯¹« µûÀ§¸¦ ¾Ë±â À§ÇÏ¿© ÇǸ¦ »Ì¾Æ ÇàÇÏ´Â °Ë»ç. ¸ö ÀüüÀÇ Àå±â³ª Á¶Á÷¿¡ º´ÅͰ¡ ÀÖÀ¸¸é ÀÌµé ¼ººÐ¿¡ º¯È°¡ ÀÖ°Ô µÇ¾î Áø´Ü¿¡ Å« µµ¿òÀ» ÁØ´Ù. |
||
| PCF | peripheral circulatory failure; pharyngoconjunctival fever; platelet complement fixation; posterior ... |
|---|---|
| TPCF | Treponema pallidum complement fixation |
| CAT | California Achievement Test; capillary agglutination test; catalase; cataract; catecholamine; Childr... |
| TAT | tetanus antitoxin; thematic apperception test; thematic aptitude test; thrombin-antithrombin complex... |
| CRL | cell repository line; Certified Record Librarian; complement receptor location; complement receptor ... |
| fixation, ocular | The direction of the gaze so that the visual image of the object falls on the fovea centralis of the retina, the area of the most acute vision. (12 Dec 1998) |
|---|---|
| fixation reaction | <immunology> Binding of complement as a result of its interaction with immune complexes (the classical pathway) or particular surfaces (alternative pathway). (18 Nov 1997) |
| fracture fixation | The use of metallic devices inserted into or through bone to hold a fracture in a set position and alignment while it heals. (12 Dec 1998) |
| fracture fixation, internal | The use of internal devices (metal plates, nails, rods, etc.) to hold the position of a fracture in proper alignment. (12 Dec 1998) |
| latex fixation tests | Passive agglutination tests in which antigen is adsorbed onto latex particles which then clump in the presence of antibody specific for the adsorbed antigen. (12 Dec 1998) |
| line of fixation | A line joining the object (or point of fixation) with the fovea. (05 Mar 2000) |
| male chromosome complement | The large majority of males have a 46, xy chromosome complement (46 chromosomes including an x and a y chromosome). A minority of males have other chromosome constitutions such as 47,xxy (47 chromosomes including two x chromosomes and a y chromosome) and 47,xyy (47 chromosomes including an x and two y chromosomes). (12 Dec 1998) |
| genetic complement | <biology, genetics> The set of chromosomes contained within any one particular cell. (07 May 1998) |
| receptors, complement | Molecules on the surface of some B-lymphocytes and macrophages, that recognise and combine with the c3b, c3d, c1q, and c4b components of complement. (12 Dec 1998) |
| receptors, complement 3b | Molecular sites on or in some B-lymphocytes and macrophages that recognise and combine with complement 3b. The primary structure of these receptors reveal that they contain transmembrane and cytoplasmic domains, with their extracellular portion composed entirely of thirty short consensus repeats each having 60 to 70 amino acids. (12 Dec 1998) |
| receptors, complement 3d | Molecular sites on or in B-lymphocytes, follicular dendritic cells, lymphoid cells, and epithelial cells that recognise and combine with complement 3d. Human cr2 serves as a receptor for both c3dg and the gp350/220 glycoprotein of herpes virus 4, human, and binds the monoclonal antibody okb7, which blocks binding of both ligands to the receptor. (12 Dec 1998) |
| chromosome complement | The whole set of chromosomes for the species. In humans, the chromosome complement (which is also called the karyotype) consists of 46 chromosomes. (12 Dec 1998) |
| complement | <immunology> A term originally used to refer to the heat labile factor in serum that causes immune cytolysis, the lysis of antibody coated cells and now referring to the entire functionally related system comprising at least 20 distinct serum proteins that is the effector not only of immune cytolysis but also of other biologic functions. Complement activation occurs by two different sequences, the classic and alternative pathways. The proteins of the classic pathway are termed components of complement and are designated by the symbols C1 through C9. C1 is a calcium dependent complex of three distinct proteins C1q, C1r and C1s. The proteins of the alternative pathway (collectively referred to as the properdin system) and complement regulatory proteins are known by semisystematic or trivial names. Fragments resulting from proteolytic cleavage of complement proteins are designated with lower case letter suffixes, for example, C3a. Inactivated fragments may be designated with the suffix i, for example C3bi. Activated components or complexes with biological activity are designated by a bar over the symbol for example C1 or C4b, 2a. The classic pathway is activated by the binding of C1 to classic pathway activators, primarily antigen-antibody complexes containing IgM, IgG1, IgG3, C1q binds to a single IgM molecule or two adjacent IgG molecules. The alternative pathway can be activated by IgA immune complexes and also by nonimmunologic materials including bacterial endotoxins, microbial polysaccharides and cell walls. Activation of the classic pathway triggers an enzymatic cascade involving C1, C4, C2 and C3, activation of the alternative pathway triggers a cascade involving C3 and factors B, D and P. Both result in the cleavage of C5 and the formation of the membrane attack complex. Complement activation also results in the formation of many biologically active complement fragments that act as anaphylatoxins, opsonins or chemotactic factors. (05 Jan 1998) |
| complement 1 | The first complement component to act in the cytolysis reaction. It is a trimolecular complex held together with ca ions and when activated, has esterase activity which initiates the next step in the sequence. (12 Dec 1998) |
| complement 1 inactivators | Compounds which inhibit, antagonise, or inactivate complement 1. A well-known inhibitor is a serum glycoprotein believed to be alpha-2-neuroaminoglycoprotein. It inhibits the activated (esterase) form of complement 1 as well as kinin-forming, coagulation, and fibrinolytic systems. Deficiency of this inactivator has been found in patients with hereditary angioneurotic oedema. These compounds are members of the serpin superfamily. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|